Rosenberger, Georg <br/><br/>
Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome.  [electronic resource] 

 -  Human mutation  Mar 2009 
 - 352-62 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1098-1004 
<br/><br/><label>Standard No.: </label>10.1002/humu.20855  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abnormalities, Multiple--genetics<br/>Cells, Cultured<br/>Chromones--pharmacology<br/>Craniofacial Abnormalities<br/>Enzyme Inhibitors--pharmacology<br/>Epidermal Growth Factor--pharmacology<br/>Failure to Thrive--pathology<br/>Fibroblasts--drug effects<br/>Guanosine Triphosphate--metabolism<br/>Humans<br/>Immunoblotting<br/>Intellectual Disability--pathology<br/>MAP Kinase Kinase 1--metabolism<br/>MAP Kinase Kinase 2--metabolism<br/>Morpholines--pharmacology<br/>Mutation<br/>Phosphatidylinositol 3-Kinases--metabolism<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Phosphorylation--drug effects<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Proto-Oncogene Proteins p21(ras)--genetics<br/>Signal Transduction--drug effects<br/>Skin--drug effects<br/>Skin Abnormalities<br/>Syndrome